Canada Life’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
Canada Life's PTGX Position: Q1 2026 in Review
Canada Life reduced its Protagonist Therapeutics (PTGX) stake by 4.4% in Q1 2026, selling an estimated $195K and leaving 47,440 shares worth $5M. The position accounts for 0.01% of the portfolio, ranked #750.
Canada Life first reported a position in PTGX in Q4 2020 and has held it in 22 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- Canada Life held 47,440 shares of Protagonist Therapeutics worth $5M as of Q1 2026.
- Canada Life sold 2,200 Protagonist Therapeutics shares in Q1 2026, an estimated $195K.
- Protagonist Therapeutics made up 0.01% of Canada Life's portfolio in Q1 2026, its #750 holding.
- Canada Life first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 22 quarters since.
- 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.